Biological
NicVAX vaccine
NicVAX vaccine is a biological therapy with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
4
67%
Ph phase_2
1
17%
Phase Distribution
0
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(6)
Detailed Status
Completed6
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (20.0%)
Phase 34 (80.0%)
Trials by Status
completed6100%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_2
Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)
NCT00995033
completedphase_3
A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers
NCT01375933
completed
A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation
NCT01304810
completedphase_3
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
NCT01102114
completedphase_3
NicVAX/Placebo as an Aid for Smoking Cessation
NCT00836199
Clinical Trials (6)
Showing 6 of 6 trials
NCT00995033Phase 2
Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)
NCT01375933Phase 3
A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers
NCT01304810
A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation
NCT01102114Phase 3
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
NCT00836199Phase 3
NicVAX/Placebo as an Aid for Smoking Cessation
NCT01178346Phase 3
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6